Pharma & Biotech
Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge
The divergence between Ocugen's scientific trajectory and its stock price has rarely been starker. The biotech's shares closed at €1.05...
Novo Nordisk’s Data Breach and Clinical Defeat Leave Investors with Little to Cheer
The Danish drugmaker entered the week with a promising oral medication and emerged facing a cybersecurity crisis and a clinical...
BioNTech Bets Big on Oncology as $1 Billion Buyback and First FDA Filing Converge
The Mainz-based biotech firm finds itself in an unusual position: burning through cash on R&D while sitting on a €16.8...
BioNTech at a Crossroads: FDA Filing Looms as Phase 3 Pipeline Takes Shape
The shares trade at €77 — roughly 27% below the 52-week high and below both their 50-day and 200-day moving...
Ocugen’s Mutation-Agnostic Gene Therapy Edges Toward FDA Filing as $130M Financing Secures Runway to 2028
Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400,...
Bayer’s Slow Build: Clinical Evidence and Margin Pressures Define the Next Chapter
Bayer is attempting to write a new chapter, one built on clinical proof rather than corporate promises. The German conglomerate's...
BioNTech’s Oncology Data Wows, but the Stock Won’t Budge: A $1 Billion Buyback Meets Investor Skepticism
The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for...
Novo Nordisk’s 15 Billion Kroner Buyback Sends a Message, but the Market Isn’t Listening
The Danish drugmaker is buying back its own stock at a furious pace just as the shares slide toward a...
Bayer’s Summer of Reckoning: Legal Decisions and a Potential Blockbuster Collide
Bayer’s stock is caught in a familiar squeeze: strong operational performance and promising drug data are consistently overshadowed by the...
Newron’s Steep Descent Accelerates as Evenamide Hopes Hinge on Conference Circuit
The sell-off in Newron Pharmaceuticals has shown no signs of letting up. Shares closed last Friday at €13.15, marking a...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
